JP2007531519A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007531519A5 JP2007531519A5 JP2007506082A JP2007506082A JP2007531519A5 JP 2007531519 A5 JP2007531519 A5 JP 2007531519A5 JP 2007506082 A JP2007506082 A JP 2007506082A JP 2007506082 A JP2007506082 A JP 2007506082A JP 2007531519 A5 JP2007531519 A5 JP 2007531519A5
- Authority
- JP
- Japan
- Prior art keywords
- gene
- nucleotide sequence
- relaxin
- recombinant adenovirus
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000701161 unidentified adenovirus Species 0.000 claims description 51
- 229920001850 Nucleic acid sequence Polymers 0.000 claims description 50
- 210000004027 cells Anatomy 0.000 claims description 28
- 108090000103 Relaxin Proteins 0.000 claims description 25
- 102000003743 Relaxin Human genes 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 210000001519 tissues Anatomy 0.000 claims description 8
- 241000700605 Viruses Species 0.000 claims description 7
- 230000000259 anti-tumor Effects 0.000 claims description 6
- 210000004881 tumor cells Anatomy 0.000 claims description 6
- 230000003612 virological Effects 0.000 claims description 6
- 230000006907 apoptotic process Effects 0.000 claims description 5
- 210000002744 Extracellular Matrix Anatomy 0.000 claims description 4
- 241000432074 Adeno-associated virus Species 0.000 claims description 3
- 241000700618 Vaccinia virus Species 0.000 claims description 3
- 230000035515 penetration Effects 0.000 claims description 3
- 208000009889 Herpes Simplex Diseases 0.000 claims description 2
- 241000713666 Lentivirus Species 0.000 claims description 2
- 241000700584 Simplexvirus Species 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000010189 intracellular transport Effects 0.000 claims 1
- 230000014509 gene expression Effects 0.000 description 11
- 238000001476 gene delivery Methods 0.000 description 10
- 230000022983 regulation of cell cycle Effects 0.000 description 7
- 102000033243 CDKN2A Human genes 0.000 description 6
- 230000001177 retroviral Effects 0.000 description 6
- 241000701022 Cytomegalovirus Species 0.000 description 5
- 230000000890 antigenic Effects 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 102100019730 TP53 Human genes 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 4
- 230000002147 killing Effects 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 230000002142 suicide Effects 0.000 description 4
- 102000006601 Thymidine Kinase Human genes 0.000 description 3
- 108020004440 Thymidine Kinase Proteins 0.000 description 3
- 230000001085 cytostatic Effects 0.000 description 3
- 239000000824 cytostatic agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 108091007521 restriction endonucleases Proteins 0.000 description 3
- 230000002588 toxic Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 102100007788 APC Human genes 0.000 description 2
- 101710022338 CDKN2A Proteins 0.000 description 2
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 210000000987 Immune System Anatomy 0.000 description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- 102100017022 MEOX2 Human genes 0.000 description 2
- 101700005432 MEOX2 Proteins 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 108050002653 Retinoblastoma Protein Proteins 0.000 description 2
- 210000003802 Sputum Anatomy 0.000 description 2
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 230000001472 cytotoxic Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037240 fusion proteins Human genes 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 210000004962 mammalian cells Anatomy 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000001402 polyadenylating Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000001105 regulatory Effects 0.000 description 2
- 201000000582 retinoblastoma Diseases 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 1
- 101710006746 7.5K Proteins 0.000 description 1
- 101700033661 ACTB Proteins 0.000 description 1
- 102100011550 ACTB Human genes 0.000 description 1
- 101710032514 ACTI Proteins 0.000 description 1
- 108010038310 Adenomatous Polyposis Coli Protein Proteins 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 102000012936 Angiostatins Human genes 0.000 description 1
- 101710012182 At1g14910 Proteins 0.000 description 1
- 102000036638 BRCA1 Human genes 0.000 description 1
- 108010042977 BRCA1 Protein Proteins 0.000 description 1
- 108010000750 BRCA2 Protein Proteins 0.000 description 1
- 102000002280 BRCA2 Protein Human genes 0.000 description 1
- 102100019398 CDK4 Human genes 0.000 description 1
- 101700008359 CDK4 Proteins 0.000 description 1
- 102100016705 COL18A1 Human genes 0.000 description 1
- 102100006400 CSF2 Human genes 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 210000000349 Chromosomes Anatomy 0.000 description 1
- 229920001405 Coding region Polymers 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 231100000776 Exotoxin Toxicity 0.000 description 1
- 102100003082 FASLG Human genes 0.000 description 1
- 108010039471 Fas Ligand Protein Proteins 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N Ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 Ganciclovir Drugs 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- AAFYOVPTFNNVDN-UHFFFAOYSA-N N-methyl-N-phenacylnitrous amide Chemical compound O=NN(C)CC(=O)C1=CC=CC=C1 AAFYOVPTFNNVDN-UHFFFAOYSA-N 0.000 description 1
- 102000007530 Neurofibromin 1 Human genes 0.000 description 1
- 241001028048 Nicola Species 0.000 description 1
- 229940067631 Phospholipids Drugs 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 210000004011 Plasma Cells Anatomy 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000724205 Rice stripe tenuivirus Species 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 102100017680 SMAD4 Human genes 0.000 description 1
- 101700062085 SMAD4 Proteins 0.000 description 1
- 102100017517 SUB1 Human genes 0.000 description 1
- 101710037124 TEK Proteins 0.000 description 1
- 102100002915 TPPP2 Human genes 0.000 description 1
- 231100000765 Toxin Toxicity 0.000 description 1
- 210000002845 Virion Anatomy 0.000 description 1
- 102100008060 WT1 Human genes 0.000 description 1
- 101700062995 WT1 Proteins 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000001772 anti-angiogenic Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000038129 antigens Human genes 0.000 description 1
- 108091007172 antigens Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 230000000139 costimulatory Effects 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000593 degrading Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002972 spermatoprotective Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 230000002103 transcriptional Effects 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 230000001052 transient Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Description
ãããã£ãŠãæ¬çºæã®ç®çã¯ããªã©ã¯ã·ã³(relaxin)âãšã³ã³ãŒãã£ã³ã°ãã¯ã¬ãªããé
åãå«ãæ°èŠéºäŒåäŒéã·ã¹ãã ãæäŸããããšã«ããã
æ¬çºæã®äžæ§æ
ã«ãããšãæ¬çºæã¯ã现èå
ã«éæ¬ããããšããç®çãã¯ã¬ãªããé
åãå«ãéºäŒåäŒéã·ã¹ãã ã«ãããŠãåèšéºäŒåäŒéã·ã¹ãã ã¯ããªã©ã¯ã·ã³(relaxin)âãšã³ã³ãŒãã£ã³ã°ãã¯ã¬ãªããé
åãè¿œå çã«å«ã¿ãåèšãªã©ã¯ã·ã³ã¯ãåèšç®çãã¯ã¬ãªããé
åã®çŽ°èå
éæ¬å¹çãå¢å ãããäœçšãããããšãç¹åŸŽãšããéºäŒåäŒéã·ã¹ãã ãæäŸããã
æ¬çºæã®éºäŒåäŒéã·ã¹ãã ã補é ããããã«ããªã©ã¯ã·ã³âãšã³ã³ãŒãã£ã³ã°ãã¯ã¬ãªããé
åã¯ãé©åããçºçŸã³ã³ã¹ãã©ã¯ã(Expression construct)å
ã«ååšããããšã奜ãŸãããåèšçºçŸã³ã³ã¹ãã©ã¯ãã«ãããŠããªã©ã¯ã·ã³éºäŒåã¯ãããã¢ãŒã¿ãŒã«äœåçã«é£çµãããããšã奜ãŸãããæ¬æ现æžã«ãããŠãçšèªâäœåçã«çµåãããâã¯ãæ žé
žçºçŸèª¿ç¯é
å(äŸãã°ãããã¢ãŒã¿ãŒãã·ã°ãã«é
åããŸãã¯è»¢å調ç¯å åçµåäœçœ®ã®ã¢ã¬ã€)ãšä»ã®æ žé
žé
åãšã®éã®æ©èœçãªçµåãæå³ããããã«ãããåèšèª¿ç¯é
åã¯ãåèšä»ã®æ žé
žé
åã®è»¢ååã³/ãŸãã¯è§£èªã調ç¯ããããã«ãªããæ¬çºæã«ãããŠããªã©ã¯ã·ã³éºäŒåã«çµåãããããã¢ãŒã¿ãŒã¯ã奜ãŸããã¯ãåç©çŽ°èããã奜ãŸããã¯ãåºä¹³åç©çŽ°èã§äœåãããªã©ã¯ã·ã³éºäŒåã®è»¢åã調ç¯ããããšãã§ãããã®ã§ãã£ãŠãåºä¹³åç©ãŠã€ã«ã¹ç±æ¥ã®ããã¢ãŒã¿ãŒåã³åºä¹³åç©çŽ°èã®ã²ãã ç±æ¥ã®ããã¢ãŒã¿ãŒãå«ã¿ãäŸãã°ãïŒïŒ¶(Cytomegalo virus)ããã¢ãŒã¿ãŒãã¢ãããŠã€ã«ã¹åŸæããã¢ãŒã¿ãŒãã¯ã¯ã·ãã¢ãŠã€ã«ã¹ïŒïŒïŒKããã¢ãŒã¿ãŒãïŒïŒããã¢ãŒã¿ãŒãã®ïœïœããã¢ãŒã¿ãŒãããã¢ãŒã¿ãŒãïŒã¢ã«ãã¡ããã¢ãŒã¿ãŒãã¡ã¿ãããªãã€ã³ããã¢ãŒã¿ãŒãããŒã¿âã¢ã¯ãã³ããã¢ãŒã¿ãŒãããâïŒéºäŒåã®ããã¢ãŒã¿ãŒãããéºäŒåã®ããã¢ãŒã¿ãŒãããâïŒéºäŒåã®ããã¢ãŒã¿ãŒããããªã³ãããã·ã³éºäŒåã®ããã¢ãŒã¿ãŒãåã³ããïŒâéºäŒåã®ããã¢ãŒã¿ãŒãå«ãããããã«éå®ããããã®ã§ã¯ãªããæã奜ãŸããã¯ãïŒïŒ¶ããã¢ãŒã¿ãŒã§ããã
奜ãŸããã¯ãæ¬çºæã«å©çšãããçºçŸã³ã³ã¹ãã©ã¯ãã¯ãããªã¢ããã«åé
åãå«ã(äŸãã°ãçæé·ãã«ã¢ã³ã¿ãŒãããŒã¿ãŒåã³ïŒ³ïŒ¶ïŒïŒç±æ¥ããªã¢ããã«åé
å)ã
æ¬çºæã®å¥œãŸããå
·çŸäŸã«ãããšãæ¬çºæã«å©çšããããªã©ã¯ã·ã³âãšã³ã³ãŒãã£ã³ã°ãã¯ã¬ãªããé
åã¯ãâããã¢ãŒã¿ãŒâãªã©ã¯ã·ã³âãšã³ã³ãŒãã£ã³ã°ãã¯ã¬ãªããé
åâããªã¢ããã«åé
åâã®æ§é ãæããã
æ¬çºæã®éºäŒåäŒéã·ã¹ãã ã«ãããŠã现èå
ã«éæ¬ããããšããç®çã®ãã¯ã¬ãªããé
åããäžè¿°ã®ãªã©ã¯ã·ã³éºäŒåã®çºçŸã³ã³ã¹ãã©ã¯ããšåäžãªæ¹æ³ã«ããçºçŸã³ã³ã¹ãã©ã¯ãã«æ§ç¯ããããšãã§ããã
æ¬çºæã§çŽ°èå
ã«éæ¬ããããšããç®çãã¯ã¬ãªããé
åã¯ããããªããã¯ã¬ãªããé
åã§ãå¯èœã§ãã£ãŠãäŸãã°ãç现èã®æ»æ»
ãèªå°ããŠã究極çã«è
«çãéåãããçæ²»çéºäŒåãšããŠãè
«çæå¶éºäŒåãå
ç«èª¿ç¯éºäŒå[äŸãã°ããµã€ãã«ã€ã³éºäŒåãã±ã¢ã«ã€ã³éºäŒåãåã³å
±åºæ¿å å(Costimulatory factor:B7.1ãšB7.2ã®ãããªT现è掻æ§ã«å¿
èŠãªè£å©åå)]ãæåæ§éºäŒåãèªæ®ºéºäŒåã现èæ¯æ§éºäŒåã现èå¢æ®æå¶éºäŒåã芪â现èæ»æ»
éºäŒåãåã³æâæ°çè¡ç®¡çæéºäŒåãå«ãŸããããããã«éå®ããããã®ã§ã¯ãªãã
èªæ®ºéºäŒåã¯ã现èãå€éšå åã«ãã殺å·ããæããªãããã«èªå°ããç©è³ªãçºçŸãããã现èã«æ¯æ§æ¡ä»¶ãèªçºããæ žé
žé
åã§ããããã®ãããªèªæ®ºéºäŒåãšããŠããç¥ãããŠãããã®ã¯ããããžã³ãããŒãŒ(TK)éºäŒåã§ãã(ç±³åœç¹èš±ç¬¬5,631,236å·åã³ç¬¬5,601,818å·)ãéºäŒåç£ç©ãçºçŸãã现èã¯ãã¬ã³ã·ã¯ããã«(gancyclovir)ã®æäžã«ããéžæçãªæ»æ»
ã«ææã§ãããè
«çæå¶éºäŒåã¯ãè
«çã®åœ¢æãæå¶ããããªãããããæå·åããéºäŒåãæå³ãããè
«çæå¶éºäŒåã¯ãåºä¹³åç©ã«ãããŠèªç¶çºçéºäŒåã§ããããã®éºäŒåã®æ¬ 倱ãŸãã¯äžæŽ»æ§åã¯ãè
«ççºçã«å¿
é åæãšãããŠãããè
«çæå¶éºäŒåã®äŸãšããŠã¯ããïŒãâïŒãâïŒãïŒïŒŽïŒ³ïŒãïŒãïŒãïŒããïœïŒïŒãïœãïŒïŒïŒ¡ïŒ£âïŒãïŒïŒïŒ³ïŒ£âïŒã網èèœçŽ°èè
«éºäŒå(Lee et al. Nature, 329:642(1987))ã倧è
žè
ºè
«çéºäŒåèçœè³ª(adenomatous polyposis coli protein;ç±³åœç¹èš±ç¬¬5,783,666å·)ãæè²äœïŒïœïŒïŒïŒïŒã«äœçœ®ãã錻åœåè
«çæå¶å åéºäŒå(Cheng et al. Proc. Nat .Acad. Sci., 95:3042-3047(1998))ãæ¬ æãããè¡æŒ¿è
«ç(DCC)éºäŒåãïŒïŒŽïŒ³ïŒãïŒããïœïŒïŒïŒïŒ²ïœãïœïŒïŒãåã³ïœïŒïŒãå«ãè
«çæå¶éºäŒåã®ïŒ©ïŒ®ïŒ«ïŒç³»åã®äžå¡åã³ããã®æ²»çåŠçã«æå¹ãªæç(äŸãã°ãp56Rbãp94Rbãªã©)ãå«ãŸãããåœæ¥è
ãªããåèšäŸç€ºããéºäŒåã«éå®ãããããã®ä»ã«ç¥ãããããããæè
«çéºäŒåãæ¬çºæã«äœ¿çšã§ãããšããããšãåããã ããã
æ¬æ现æžã«ãããŠãçšèªâæåæ§éºäŒå(antigenic gene)âã¯ãã¿ãŒã²ãã现èå
ã§çºçŸãããŠãå
ç«ã·ã¹ãã ã§èªèã§ãã现èè¡šé¢æåæ§èçœè³ªãçç£ãããã¯ã¬ãªããé
åãæå³ããããã®ãããªæåæ§éºäŒåã®äŸã«ã¯ãçèå
æ§æå(carcinoembryonic antigen, CEA)åã³ïŒ°ïŒ³ïŒ¡(prostate specific antigen)ã(α-feto protein)ãïœïŒïŒ(WO 94/02167)ãå«ãŸãããå
ç«ã·ã¹ãã ã容æã«èªèããããã«ããããã«ãåèšæåæ§éºäŒåãïŒïŒšïŒ£ç¬¬ïŒ©åæåã«çµåãããããšãã§ããã
æ¬æ现æžã«ãããŠãçšèªâ现èæ¯æ§éºäŒå(Cytotoxic gene)âã¯ã现èå
ã§çºçŸãããŠæ¯æ§å¹æã瀺ããã¯ã¬ãªããé
åãæå³ããããã®ãããªçŽ°èæ¯æ§éºäŒåã®äŸã«ã¯ãã·ã¥ãŒãã¢ãã¹å€æ¯çŽ (exotoxin)ããªã·ã³æ¯çŽ ããžãããªã¢æ¯çŽ ãªã©ãã³ãŒãã£ã³ã°ãããã¯ã¬ãªããé
åãå«ãŸããã
æ¬æ现æžã«ãããŠãçšèªâ现èå¢æ®æå¶éºäŒå(cytostatic gene)âã¯ã现èå
ã§çºçŸãããŠã现èåšæéäžã«çŽ°èåšæãåæ¢ããããã¯ã¬ãªããé
åãæå³ããããã®ãããªçŽ°èå¢æ®æå¶éºäŒåã®äŸã«ã¯ãïœïŒïŒã網èèœçŽ°èè
«éºäŒåãïŒïŒŠâïœèåèçœè³ªéºäŒåãã·ã¯ãªã³âåŸå±æ§ãããŒãŒæå¶å åãã³ãŒãã£ã³ã°ããéºäŒå(äŸãã°ãp16ãp15ãp18åã³p19)ãæé·äžæ¢ç¹ç°æ§ãã¡ãªããã¯ã¹(growth arrest specific homeobox, GAX)éºäŒå(WO 97/16459åã³WO 96/30385)ãªã©ãããããããã«éå®ããããã®ã§ã¯ãªãã
æ¬æ现æžã«ãããŠãçšèªâ芪â现èæ»æ»
éºäŒå(Pro-apoptotic gene)âã¯ãçºçŸãããŠãããã°ã©ã ããã现èæ¶æ»
ãèªå°ãããã¯ã¬ãªããé
åãæå³ããããã®ãããªèŠªâ现èæ»æ»
éºäŒåã®äŸã«ã¯ãïœïŒïŒãã¢ãããŠã€ã«ã¹ïŒ¥ïŒâïŒïŒïŒïŒïŒ«(ïœïŒåã³ïŒ¡ïœïŒç±æ¥)ãŸãã¯ã¢ãããŠã€ã«ã¹ïŒ¥ïŒâïŒïŒïŒïŒïŒ«(ïœç±æ¥)ãã¢ãããŠã€ã«ã¹ïŒ¥ïŒéºäŒåãïœïœãªã¬ã³ããâαããïœïŒïŒçµè·¯éºäŒååã³ã«ã¹ããŒãŒãã³ãŒãã£ã³ã°ããéºäŒåãå«ãŸããã
æ¬çºæã®æ现æžã«ãããŠãçšèªâæâæ°çè¡ç®¡çæéºäŒå(anti-angiogenic gene)âã¯ãçºçŸãããŠãæâæ°çè¡ç®¡çæå åã现èå€ã«æŸåºãããã¯ã¬ãªããé
åãæå³ãããæâæ°çè¡ç®¡çæå åã«ã¯ãã¢ã³ãžãªã¹ã¿ãã³ãïœïœ
ïŒ(PNAS, 1998, 95,8795-800)ã®ãããªè¡ç®¡å
ç®æé·å å(VEGF)ã®æå¶å åããšã³ãã¹ã¿ãã³ãªã©ãå«ãŸããã
äžè¿°ã®ç®çã®ãã¯ã¬ãªããé
åã¯ãïœ
ïœïŒ¢ïœïœïœãŸãã¯ïŒ¥ïŒïŒ¢ïŒ¬ã®ãããªïŒ€ïŒ®ïŒ¡é
åããŒã¿ãã³ã¯ããå
¥æã§ããã
ãªã©ã¯ã·ã³âãšã³ã³ãŒãã£ã³ã°ãã¯ã¬ãªããé
åã¯ãéåžžçãªéºäŒåæ²»çã«å©çšãããå
šãŠã®éºäŒåäŒéã·ã¹ãã ã«é©çšã§ããŠã奜ãŸããã¯ããã©ã¹ãããã¢ãããŠã€ã«ã¹(Lockett LJ, et al., Clin. Cancer Res. 3:2075-2080(1997))ãã¢ããâé¢é£ãŠã€ã«ã¹(Adeno-associated viruses: AAV, Lashford LS., et al., Gene Therapy Technologies, Applications and Regulations Ed. A. Meager, 1999)ãã¬ãããŠã€ã«ã¹(Gunzburg WH, et al., Retroviral vectors. Gene Therapy Technologies, Applications and Regulations Ed. A. Meager, 1999)ãã¬ã³ããŠã€ã«ã¹(Wang G. et al., J. Clin. Invest. 104(11):R55-62(1999))ãåçŽãã«ãã¹ãŠã€ã«ã¹(Chamber R., et al., Proc. Natl. Acad. Sci USA 92:1411-1415(1995))ãã¯ã¯ã·ãã¢ãŠã€ã«ã¹(Puhlmann M. et al., Human Gene Therapy 10:649-657(1999))ããªããœãŒã (Methods in Molecular Biology, Vol 199, S.C. Basu and M. Basu (Eds.), Human Press 2002)ããŸãã¯ããªãœãŒã ã«é©çšã§ãããæã奜ãŸããã¯ãæ¬çºæã®éºäŒåäŒéã·ã¹ãã ã¯ããªã©ã¯ã·ã³âãšã³ã³ãŒãã£ã³ã°ãã¯ã¬ãªããé
åãã¢ãããŠã€ã«ã¹ã«é©çšããŠè£œé ãããã
çŸåšéçºãããã¢ãããŠã€ã«ã¹ãã¯ã¿ãŒã®äžã§ãïŒé åã®æ¬ åŠãããè€è£œäžèœã¢ãããŠã€ã«ã¹ãããå©çšãããŠãããäžæ¹ãïŒé åã¯ãéåžžçãªã¢ãããŠã€ã«ã¹ãã¯ã¿ãŒããé€å»ãããå€æ¥éºäŒåãæ¿å
¥ããã座ãæäŸãã(Thimmappaya, B. et al., Cell, 31:543-551(1982); Riordan, J. R. et al., Science, 245:1066-1073(1989))ããããã£ãŠãæ¬çºæã®ãªã©ã¯ã·ã³éºäŒåã¯ãæ¬ å€±ãããïŒé å(E1Aé ååã³/ãŸãã¯E1Bé åã奜ãŸããã¯ãE1Bé å)ããŸãã¯ïŒ¥ïŒé åã«æ¿å
¥ãããããšã奜ãŸããããã奜ãŸããã¯ãæ¬ å€±ãããïŒé åã«æ¿å
¥ããããäžæ¹ã现èå
ã«éæ¬ããããšããç®çãã¯ã¬ãªããé
åã¯ãæ¬ å€±ãããïŒé å(E1Aé ååã³/ãŸãã¯E1Bé åã奜ãŸããã¯ãE1Bé å)ããŸãã¯ïŒ¥ïŒé åã«æ¿å
¥ãããããšã奜ãŸããããã奜ãŸããã¯ãæ¬ å€±ãããïŒé åã«æ¿å
¥ãããããŸããåèšæ¿å
¥é
åã¯ãæ¬ å€±ãããïŒé åã«ãæ¿å
¥ã§ãããæ¬æ现æžã«ãããŠããŠã€ã«ã¹ã²ãã é
åãšé¢é£ããŠäœ¿çšãããçšèªãâæ¬ å€±âã¯ã該åœé
åãå®å
šã«æ¬ 倱ããããã®ã ãã§ã¯ãªããéšåçã«æ¬ 倱ããããã®ãå«ãæå³ãæããã
æ¬çºæã®æã奜ãŸããå
·çŸäŸã«ãããšãæ¬çºæã®ã¢ãããŠã€ã«ã¹éºäŒåäŒéã·ã¹ãã ã¯ãâããã¢ãŒã¿ãŒâç®çãã¯ã¬ãªããé
åâããªïŒ¡é
åâãšâããã¢ãŒã¿ãŒâãªã©ã¯ã·ã³éºäŒåâããªïŒ¡é
åâãšãé£çµãããæ§é ãæããŠãåèšâããã¢ãŒã¿ãŒâç®çãã¯ã¬ãªããé
åâããªïŒ¡é
åâã¯ãæ¬ å€±ãããïŒé å(E1Aé ååã³/ãŸãã¯E1Bé åã奜ãŸããã¯ãE1Bé å)ããŸãã¯ïŒ¥ïŒé åã奜ãŸããã¯ãæ¬ å€±ãããïŒé åã«æ¿å
¥ããããã®ã§ãããåèšâããã¢ãŒã¿ãŒâãªã©ã¯ã·ã³éºäŒåâããªïŒ¡é
åâã¯ãæ¬ å€±ãããïŒé å(E1Aé ååã³/ãŸãã¯E1Bé åã奜ãŸããã¯ãE1Bé å)ããŸãã¯ïŒ¥ïŒé åã奜ãŸããã¯ãæ¬ å€±ãããïŒé åã«æ¿å
¥ããããã®ã§ããããŸããâããã¢ãŒã¿ãŒâç®çãã¯ã¬ãªããé
åâããªïŒ¡é
åââãªã©ã¯ã·ã³éºäŒåâããªïŒ¡é
åâã®ããã«ãç®çãã¯ã¬ãªãããšãªã©ã¯ã·ã³éºäŒåã(internal ribosome entry site)ã«ããé£çµããããã€ã·ã¹ããã³(bicistronic)çºçŸã·ã¹ãã ã«ãã£ãŠãçºçŸå¯èœã§ããã
ãŸããã¢ãããŠã€ã«ã¹ã¯ãéçåã²ãã ã®çŽïŒïŒïŒïŒ
ãŸã§ããã±ãŒãžã³ã°ããããšãã§ãããããçŽïŒïœïœãè¿œå çã«ããã±ãŒãžã³ã°ããããšãã§ãã(Ghosh-Choudhury et al., EMBO J., 6:1733-1739(1987))ããããã£ãŠãã¢ãããŠã€ã«ã¹ã«æ¿å
¥ãããäžè¿°ã®å€æ¥é
åã¯ãã¢ãããŠã€ã«ã¹ã®ã²ãã ã«è¿œå çã«çµåãããããšãã§ããã
ã¬ãããŠã€ã«ã¹ãã¯ã¿ãŒãæ§ç¯ããããã«ããªã©ã¯ã·ã³éºäŒååã³éæ¬ãããããç®çãã¯ã¬ãªããé
åã¯ãã¬ãããŠã€ã«ã¹ã®é
åã®ä»£ããã«ã¬ãããŠã€ã«ã¹ã²ãã ã«æ¿å
¥ãããŠãè€è£œäžèœã®ãŠã€ã«ã¹ãçç£ãããããªãªã³ãçç£ããããã«ãïœïœïœãïœïœïœåã³ïœ
ïœïœéºäŒåãå«ããã(long terminal repeat)ãšÐé
åã¯å«ãŸãªãããã±ãŒãžã³ã°çŽ°èæ ªãæ§ç¯ãã(Mann et al., Cell, 33:153-159(1983))ããªã©ã¯ã·ã³éºäŒåãéæ¬ããããšããç®çãã¯ã¬ãªããé
åãåã³Ðé
åãå«ãçµã¿æããã©ã¹ãããåèšçŽ°èæ ªã«ç§»å
¥ãããšãÐé
åã¯ãçµã¿æããã©ã¹ããã®ïŒ²ïŒ®ïŒ¡è»¢åäœã®çç£ãå¯èœã«ããŠããã®è»¢åäœã¯ããŠã€ã«ã¹ã«ããã±ãŒãžã³ã°ãããŠããŠã€ã«ã¹ã¯ãå¹å°ã«æåºããã(Nicolas and Rubinstein "Retroviral vectors," In: Vectors: A survey of molecular cloning vectors and their uses, Rodriguez and Denhardt (eds.), Stoneham: Butterworth, 494-513(1988))ãçµã¿æãã¬ãããŠã€ã«ã¹ãå«æããå¹å°ãåéããŠæ¿çž®ããéºäŒåäŒéã·ã¹ãã ã«å©çšããã
ïŒäžåž¯ã¬ãããŠã€ã«ã¹ãã¯ã¿ãŒãå©çšããéºäŒåäŒéãçºè¡šããããKasaharaã(Science, 266:1373-1376(1994))ã¯ãã¢ãããŒããŠã¹çœè¡ç
ãŠã€ã«ã¹(moloney-murine leukemia virus)ã®å€ç°äœã補é ããŠãããã§ã(erythropoietin)é
åããšã³ãããŒãéšäœã«æ¿å
¥ããŠãæ°ããçµåç¹æ§ãæãããã¡ãªãã¯èçœè³ª(Chimeric proteins)ãçç£ãããæ¬çºæã®éºäŒåäŒéã·ã¹ãã ãããã®ãããªïŒäžåž¯ã¬ãããŠã€ã«ã¹ãã¯ã¿ãŒã®æ§ç¯æŠç¥ã«ãã補é ããããšãã§ããã
å
žåçã«ããŠã€ã«ã¹ã¯ãäºã€ã®ïŒ¡ïŒ¡ïŒ¶æ«ç«¯ãªããŒããäž¡åŽã«äœçœ®ãããŠããç®çã®éºäŒåé
å(ãªã©ã¯ã·ã³éºäŒååã³éæ¬ããããšããç®çãã¯ã¬ãªããé
å)ãå«ããã©ã¹ãã(McLaughlin et al., J. Virol., 62:1963-1973(1988);åã³Samulski et al., J. Virol., 63:3822-3828(1989))åã³æ«ç«¯ãªããŒãã®ãªãéçåã³ãŒãã£ã³ã°é
åãå«ãçºçŸãã©ã¹ãã(McCarty et al., J. Virol., 65:2936-2945( 1991))ãåæ圢質転æãããŠè£œé ãããã
ivïŒä»ã®ãŠã€ã«ã¹ãã¯ã¿ãŒ
ä»ã®ãŠã€ã«ã¹ãã¯ã¿ãŒããæ¬çºæã®éºäŒåäŒéã·ã¹ãã ãšããŠå©çšããããšãã§ãããã¯ã¯ã·ãã¢ãŠã€ã«ã¹(Puhlmann M. et al., Human Gene Therapy 10:649-657(1999); Ridgeway, "Mammalian expression vectors," In: Vectors: A survey of molecular cloning vectors and their uses. Rodriguez and Denhardt, eds. Stoneham: Butterworth, 467-492(1988); Baichwal and Sugden, "Vectors for gene transfer derived from animal DNA viruses: Transient and stable expression of transferred genes," In: Kucherlapati R, ed. Gene transfer. New York: Plenum Press, 117-148( 1986)åã³Coupar et al., Gene, 68:1-10(1988))ãã¬ã³ããŠã€ã«ã¹(Wang G. et al., J. Clin. Invest. 104(11):R55-62(1999))ããŸãã¯åçŽãã«ãã¹ãŠã€ã«ã¹(Chamber R., et al., Proc. Natl. Acad. Sci USA 92:1411-1415(1995))ç±æ¥ã®ãã¯ã¿ãŒãããªã©ã¯ã·ã³éºäŒååã³éæ¬ããããšããç®çãã¯ã¬ãªããé åã现èå ã«éæ¬ããããšãã§ããéæ¬ã·ã¹ãã ãšããŠå©çšããããšãã§ããã
ä»ã®ãŠã€ã«ã¹ãã¯ã¿ãŒããæ¬çºæã®éºäŒåäŒéã·ã¹ãã ãšããŠå©çšããããšãã§ãããã¯ã¯ã·ãã¢ãŠã€ã«ã¹(Puhlmann M. et al., Human Gene Therapy 10:649-657(1999); Ridgeway, "Mammalian expression vectors," In: Vectors: A survey of molecular cloning vectors and their uses. Rodriguez and Denhardt, eds. Stoneham: Butterworth, 467-492(1988); Baichwal and Sugden, "Vectors for gene transfer derived from animal DNA viruses: Transient and stable expression of transferred genes," In: Kucherlapati R, ed. Gene transfer. New York: Plenum Press, 117-148( 1986)åã³Coupar et al., Gene, 68:1-10(1988))ãã¬ã³ããŠã€ã«ã¹(Wang G. et al., J. Clin. Invest. 104(11):R55-62(1999))ããŸãã¯åçŽãã«ãã¹ãŠã€ã«ã¹(Chamber R., et al., Proc. Natl. Acad. Sci USA 92:1411-1415(1995))ç±æ¥ã®ãã¯ã¿ãŒãããªã©ã¯ã·ã³éºäŒååã³éæ¬ããããšããç®çãã¯ã¬ãªããé åã现èå ã«éæ¬ããããšãã§ããéæ¬ã·ã¹ãã ãšããŠå©çšããããšãã§ããã
vïŒãªããœãŒã
ãªããœãŒã ã¯ãæ°Žäžã«åæ£ãããçè質ã«ããèªç¶ã«åœ¢æããããå€æ¥ïŒ€ïŒ®ïŒ¡ååããªããœãŒã ã«ããæåçã«çŽ°èå ã«éæ¬ããäŸã¯ãNicolauåã³Sene, Biochim. Biophys. Acta, 721:185-190(1982)ãåã³Nicolau et al., Methods Enzymol., 149:157-176(1987)ã«é瀺ãããŠãããäžæ¹ããªããœãŒã ãå©çšããåç©çŽ°èã®åœ¢è³ªè»¢æã«æãããå©çšãããè©Šè¬ãšããŠã¯ãLipofectamine(Gibco BRL)ãããããªã©ã¯ã·ã³éºäŒååã³éæ¬ããããšããç®çãã¯ã¬ãªããé åãå å ãããªããœãŒã ã¯ããšã³ããµã€ããŒã·ã¹ã现èè¡šé¢ãžã®åžçãŸãã¯ãã©ãºã现èèãšã®èåãªã©ã®ã¡ã«ããºã ãéããŠçŽ°èãšçžäºäœçšãã现èå ã«ãªã©ã¯ã·ã³éºäŒååã³éæ¬ããããšããç®çãã¯ã¬ãªããé åãéæ¬ããã
ãªããœãŒã ã¯ãæ°Žäžã«åæ£ãããçè質ã«ããèªç¶ã«åœ¢æããããå€æ¥ïŒ€ïŒ®ïŒ¡ååããªããœãŒã ã«ããæåçã«çŽ°èå ã«éæ¬ããäŸã¯ãNicolauåã³Sene, Biochim. Biophys. Acta, 721:185-190(1982)ãåã³Nicolau et al., Methods Enzymol., 149:157-176(1987)ã«é瀺ãããŠãããäžæ¹ããªããœãŒã ãå©çšããåç©çŽ°èã®åœ¢è³ªè»¢æã«æãããå©çšãããè©Šè¬ãšããŠã¯ãLipofectamine(Gibco BRL)ãããããªã©ã¯ã·ã³éºäŒååã³éæ¬ããããšããç®çãã¯ã¬ãªããé åãå å ãããªããœãŒã ã¯ããšã³ããµã€ããŒã·ã¹ã现èè¡šé¢ãžã®åžçãŸãã¯ãã©ãºã现èèãšã®èåãªã©ã®ã¡ã«ããºã ãéããŠçŽ°èãšçžäºäœçšãã现èå ã«ãªã©ã¯ã·ã³éºäŒååã³éæ¬ããããšããç®çãã¯ã¬ãªããé åãéæ¬ããã
æ¬çºæã®ãŸãä»ã®æ§æ
ã«ãããšãæ¬çºæã¯ãã¢ãããŠã€ã«ã¹ã®ïŒ©ïŒŽïŒ²(inverted terminal repeat)ãã¯ã¬ãªããé
ååã³ãªã©ã¯ã·ã³âãšã³ã³ãŒãã£ã³ã°ãã¯ã¬ãªããé
åãå«ã¿ãåèšãªã©ã¯ã·ã³ã¯ãã¢ãããŠã€ã«ã¹ã®è
«ççµç¹æµžéèœåã³è
«ç现èã¢ãããŒã·ã¹èœãå¢å€§ãããäœçšãããããšãç¹åŸŽãšããçµã¿æãã¢ãããŠã€ã«ã¹ãæäŸããã
æ¬çºæã®çµã¿æãã¢ãããŠã€ã«ã¹ã¯ãåŸæ¥ã®çµã¿æãã¢ãããŠã€ã«ã¹ã«ãªã©ã¯ã·ã³âãšã³ã³ãŒãã£ã³ã°ãã¯ã¬ãªããé
åãè¿œå çã«çµåãããã¢ãããŠã€ã«ã¹ã®è
«ççµç¹æµžéèœåã³è
«ç现èã¢ãããŒã·ã¹èœãå¢å€§ãããŠãã¢ãããŠã€ã«ã¹ã«ããçæ²»çå¹èœã倧ããå¢å ãããã
ã¢ãããŠã€ã«ã¹ã²ãã ã®å°ããéšåã ããïœïœïœã§å¿
èŠã§ãããšç¥ãããŠãããã(Tooza, J. Molecular biology of DNA Tumor viruses, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.(1981))ãã¢ãããŠã€ã«ã¹ã¯ã倧éã®å€æ¥ïŒ€ïŒ®ïŒ¡ååãéæ¬ã§ããèœåããããããã¯ç¹ã«ãïŒïŒïŒã®ãããªç¹å®çŽ°èæ ªãå©çšããå Žåã«ããã§ããããã®ãããªåŽé¢ã§ãæ¬çºæã®çµã¿æãã¢ãããŠã€ã«ã¹ã«ãããŠããªã©ã¯ã·ã³éºäŒå以å€ã®ä»ã®ã¢ãããŠã€ã«ã¹ã®é
åã¯ãå°ãªããšãé
åãå«ãã
ãªã©ã¯ã·ã³éºäŒåã¯ãïŒé å(E1Aé ååã³/ãŸãã¯E1Bé åã奜ãŸããã¯ãE1Bé å)ããŸãã¯ïŒ¥ïŒé åã«æ¿å
¥ãããããšã奜ãŸããããã奜ãŸããã¯ãïŒé åã«æ¿å
¥ããããäžæ¹ãä»ã®å€æ¥ãã¯ã¬ãªããé
å(äŸãã°ããµã€ãã«ã€ã³ãå
ç«âå
±åºæ¿å åãèªæ®ºéºäŒåãåã³è
«çæå¶éºäŒå)ãè¿œå çã«ã¢ãããŠã€ã«ã¹ã«å«ããããšãã§ããŠãããã¯ãïŒé å(E1Aé ååã³/ãŸãã¯E1Bé åã奜ãŸããã¯ãE1Bé å)ãŸãã¯ïŒ¥ïŒé åã«æ¿å
¥ãããããšã奜ãŸããããã奜ãŸããã¯ãïŒé å(E1Aé ååã³/ãŸãã¯E1Bé åã奜ãŸããã¯ãE1Bé å)ã«æ¿å
¥ãããããŸããåèšæ¿å
¥é
åã¯ãïŒé åã«ãæ¿å
¥ã§ããã
ãŸããã¢ãããŠã€ã«ã¹ã¯ãéçåã²ãã ã®çŽïŒïŒïŒïŒ
ãŸã§ããã±ãŒãžã³ã°ããããšãã§ãããããçŽïŒïœïœãè¿œå çã«ããã±ãŒãžã³ã°ããããšãã§ããããããã£ãŠãã¢ãããŠã€ã«ã¹ã«æ¿å
¥ãããäžè¿°ã®å€æ¥é
åã¯ãã¢ãããŠã€ã«ã¹ã®ã²ãã ã«è¿œå çã«çµåãããããšãã§ããã
æ¬çºæã®å¥œãŸããå
·çŸäŸã«ãããšãæ¬çºæã®çµã¿æãã¢ãããŠã€ã«ã¹ã¯ã掻æ§ã®ïŒ¥ïŒïŒ¡éºäŒåãå«ããïŒïŒ¡éºäŒåãå«ãçµã¿æãã¢ãããŠã€ã«ã¹ã¯ãè€è£œå¯èœãªç¹æ§ãæããããã«ãªããæ¬çºæã®ãã奜ãŸããå
·çŸäŸã«ãããšãæ¬çºæã®çµã¿æãã¢ãããŠã€ã«ã¹ã¯ãé掻æ§åãããïŒïŒ¢ ïŒïŒ/ïŒïŒ¢ ïŒïŒéºäŒååã³æŽ»æ§ã®ïŒ¥ïŒïŒ¡éºäŒåãå«ããæ¬çºæã®æã奜ãŸããå
·çŸäŸã«ãããšãæ¬çºæã®çµã¿æãã¢ãããŠã€ã«ã¹ã¯ãé掻æ§åãããïŒïŒ¢ ïŒïŒ/ïŒïŒ¢ ïŒïŒéºäŒååã³æŽ»æ§ã®ïŒ¥ïŒïŒ¡éºäŒåãå«ã¿ããªã©ã¯ã·ã³âãšã³ã³ãŒãã£ã³ã°ãã¯ã¬ãªããé
åã¯ãæ¬ å€±ãããïŒé åã«æ¿å
¥ãããã
æ¬çºæã®æã奜ãŸããå
·çŸäŸã«ãããšãæ¬çºæã®çµã¿æãã¢ãããŠã€ã«ã¹ã¯ãââïŒïŒ¡âÎïŒïŒ¢âããã¢ãŒã¿ãŒâãªã©ã¯ã·ã³éºäŒåâããªïŒ¡é
åâæ§é ãæããŠãåèšâããã¢ãŒã¿ãŒâãªã©ã¯ã·ã³éºäŒåâããªïŒ¡é
åâã¯ãæ¬ å€±ãããïŒé åã«æ¿å
¥ããããæ¬çºæã®çµã¿æãã¢ãããŠã€ã«ã¹ã®å¥œãŸããäžå®æœäŸã¯ãå³ïŒã«ãããŠãïœâÎïŒïŒ¢âã§è¡šãããéºäŒåå°å³ãæããã
æ¬çºæã®ä»ã®æ§æ
ã«ãããšãæ¬çºæã¯ã(a)ãªã©ã¯ã·ã³âãšã³ã³ãŒãã£ã³ã°ãã¯ã¬ãªããé
åãå«ãéºäŒåäŒéã·ã¹ãã ãŸãã¯ãªã©ã¯ã·ã³ã¿ã³ãã¯è³ªã®æ²»çåŠçæå¹éïŒåã³(b)è¬å€åŠçã«èš±å®¹ãããæ
äœãå«ã现èå€åºè³ªã®é床ãªãèç©(accumulation)ã«ä¿ãçŸæ£ãŸãã¯ç¶æ
ã®æ²»ççšè¬å€åŠççµæç©ãæäŸããã
æ¬çºæã®è¬å€åŠççµæç©ã«ãããŠããªã©ã¯ã·ã³âãšã³ã³ãŒãã£ã³ã°ãã¯ã¬ãªããé
åãå«ãéºäŒåäŒéã·ã¹ãã ã¯ãäžè¿°ããæ¬çºæã®éºäŒåäŒéã·ã¹ãã ã«ãã説æããããäžæ¹ãæ¬çºæã®è¬å€åŠççµæç©ã§å©çšããããªã©ã¯ã·ã³ã¿ã³ãã¯è³ªã¯ã倩ç¶ãœãŒã¹(natural source)ããåé¢ããããªã©ã¯ã·ã³ã¿ã³ãã¯è³ªåã³çµã¿æ¿ãæè¡ã«ããåŸããããªã©ã¯ã·ã³ã¿ã³ãã¯è³ªãå«ã¿ã现èå€åºè³ªå解掻æ§ãæããç¯å²å
ã§ãåèšã¿ã³ãã¯è³ªã®æçãå«ãŸããã
æ¬çºæã¯ããªã©ã¯ã·ã³âãšã³ã³ãŒãã£ã³ã°ãã¯ã¬ãªããé
åãå«ãæ°èŠãªéºäŒåäŒéã·ã¹ãã ãçµã¿æ¿ãã¢ãããŠã€ã«ã¹ãåèšéºäŒåäŒéã·ã¹ãã ãå©çšããéºäŒåäŒéæ¹æ³ãåèšçµã¿æãã¢ãããŠã€ã«ã¹ãå«ãè¬å€åŠçæè
«ççµæç©ãæ¹åãããçµç¹æµžéæ§ãæããè¬å€åŠççµæç©ãåã³çŽ°èå€åºè³ªã®é床ãªãèç©ã«ä¿ãçŸç
ãŸãã¯çŸæ£ã®æ²»ççšè¬å€åŠççµæç©ãæäŸãããæ¬çºæã«ãããšããªã©ã¯ã·ã³ãéºäŒåäŒéå¹çãæ¹åãããã ãã§ã¯ãªããè
«ç现èã§çŽ°èã¢ãããŒã·ã¹ãå¢å ãããŠãåªããè
«ç现è殺å·èœãå¥ããã
ãªã©ã¯ã·ã³éºäŒåãçºçŸããã¢ãããŠã€ã«ã¹ã補äœããããã«ãïœïŒ€ïŒ®ïŒ²ââ(ATCC, # MGC-14599)ãïœïœïŒ©ãšïŒšïœïœïœIIIå¶éé
µçŽ ã§åŠçããŠåŸãããïŒïœïœ åçããïœïŒ£ïŒ¡ïŒïŒãã¯ã¿ãŒ(Microbix, Ontario, Canada)ã«æ¿å
¥ãããŠãïœïŒ£ïŒ¡ïŒïŒâãã¯ã¿ãŒã補äœãããæ¬å®éšã§å©çšããããªã©ã¯ã·ã³éºäŒåã®é
åã¯ã Genbank accession No. BC005956ã«é瀺ãããŠããã補äœãããïœïŒ£ïŒ¡ïŒïŒâãïœïœIIå¶éé
µçŽ ã§åŠçãïŒïŒ¶ââïœïœïœ çºçŸã«ã»ãããåãåºããŠããããã¢ãããŠã€ã«ã¹ïŒ¥ïŒã·ã£ãã«ãã¯ã¿ãŒã§ããïœïŒ³ïŒ°ïŒïŒÎïŒ(Promega, Madison, WI, USA)ã«æ¿å
¥ããŠãïœïŒ³ïŒ°ïŒïŒÎïŒâïœïŒ²ïŒ¬ïŒž ïŒã·ã£ãã«ãã¯ã¿ãŒã補äœããã補äœãããïœïŒ³ïŒ°ïŒïŒÎïŒâïœïŒ²ïŒ¬ïŒž ïŒã·ã£ãã«ãã¯ã¿ãŒãïœïœïŒ©å¶éé
µçŽ ã§åŠçããŠåäžçãšããåŸãããŒã¿ã«ãã¯ã¿ãŒã§ããåèšïœïœïœâïœïœïŒºãšå
±ã«å€§è
žèïŒïŒïŒïŒ(Dr. Verca, University of Fribourg,ã¹ã€ã¹)㧠åæ圢質転æãããŠãéºäŒåçžåçµã¿æã(homologous recombination)ãèªå°ããïœïœâïœïœïŒºâ(ãŸãã¯ïœïœââ)ã¢ãããŠã€ã«ã¹ãã¯ã¿ãŒã補äœãã(å³ïŒ)ãåèšïœïœââã¢ãããŠã€ã«ã¹ã¯ãå¯èšæ©é¢éåœåŸ®çç©ä¿åã»ã³ã¿ãŒã«ïŒïŒïŒïŒå¹ŽïŒæïŒïŒæ¥ä»ã«ãŠå¯èšããŠãå¯èšçªå·ïŒ«ïŒ£ïŒ£ïŒâïŒïŒïŒïŒïŒãä»äžãããã
å³ïŒã«ãããŠãΚã¯ã(inverted terminal repeat)åã³ããã±ãŒãžã·ã°ãã«ãå«ãé
åã瀺ããèšå·ïŒ¡ïœã¯ãã¢ãããŠã€ã«ã¹ã瀺ããŠãïŒïŒ¶ã¯ãïŒïŒ¶ããã¢ãŒã¿ãŒã瀺ããïœïœ ã¯ãããªïŒ¡é
åã§ãããã¯ãã¿ã³ãã¯è³ªïŒ©ïŒžéºäŒåã瀺ãã
Claims (14)
- 现èå ã«éæ¬ããããšããç®çãã¯ã¬ãªããé ååã³ãªã©ã¯ã·ã³(relaxin)âãšã³ã³ãŒãã£ã³ã°ãã¯ã¬ãªããé åãå«ããŠã€ã«ã¹ãã¯ã¿ãŒãæå¹æåãšããŠå«ããåèšç®çãã¯ã¬ãªããé åã®çŽ°èå éæ¬å¹çãå¢å ãããçšéã®çµæç©ã
- åèšçŽ°èã¯ã现èå€åºè³ªã«ããé£çµããã现èãããªãçµç¹å ã®çŽ°èã§ããããšãç¹åŸŽãšããè«æ±é ïŒã«èšèŒã®çµæç©ã
- åèšçµç¹ã¯ãè «ççµç¹ã§ããããšãç¹åŸŽãšããè«æ±é ïŒã«èšèŒã®çµæç©ã
- åèšãŠã€ã«ã¹ãã¯ã¿ãŒã¯ãçµã¿æãã¢ãããŠã€ã«ã¹ãã¢ããâé¢é£ãŠã€ã«ã¹(Adeno-associated viruses: AAV)ãã¬ãããŠã€ã«ã¹ãã¬ã³ããŠã€ã«ã¹ãåçŽãã«ãã¹ãŠã€ã«ã¹ããŸãã¯ã¯ã¯ã·ãã¢ãŠã€ã«ã¹ã§ããããšãç¹åŸŽãšããè«æ±é ïŒã«èšèŒã®çµæç©ã
- åèšãŠã€ã«ã¹ãã¯ã¿ãŒã¯ãçµã¿æãã¢ãããŠã€ã«ã¹ã§ããããšãç¹åŸŽãšããè«æ±é ïŒã«èšèŒã®çµæç©ã
- åèšçµã¿æãã¢ãããŠã€ã«ã¹ã¯ãïŒé åãæ¬ å€±ããããã®ã§ãã£ãŠãåèšãªã©ã¯ã·ã³âãšã³ã³ãŒãã£ã³ã°ãã¯ã¬ãªããé åã¯ãïŒé åã®äœçœ®ã«æ¿å ¥ãããããšãç¹åŸŽãšããè«æ±é ïŒã«èšèŒã®çµæç©ã
- ã¢ãããŠã€ã«ã¹ã®ïŒ©ïŒŽïŒ²(inverted terminal repeat)ãã¯ã¬ãªããé ååã³ãªã©ã¯ã·ã³âãšã³ã³ãŒãã£ã³ã°ãã¯ã¬ãªããé åãå«ã¿ãåèšãªã©ã¯ã·ã³ã¯ãã¢ãããŠã€ã«ã¹ã®è «ççµç¹æµžéèœåã³è «ç现èã¢ãããŒã·ã¹ãèªå°ãããããã®çµã¿æãã¢ãããŠã€ã«ã¹ã
- åèšçµã¿æãã¢ãããŠã€ã«ã¹ã¯ãïŒéºäŒåé åãæ¬ å€±ããããã®ã§ãã£ãŠãåèšãªã©ã¯ã·ã³âãšã³ã³ãŒãã£ã³ã°ãã¯ã¬ãªããé åã¯ãåèšïŒ¥ïŒéºäŒåé åã®äœçœ®ã«æ¿å ¥ãããããšãç¹åŸŽãšããè«æ±é ïŒã«èšèŒã®çµã¿æãã¢ãããŠã€ã«ã¹ã
- åèšçµã¿æãã¢ãããŠã€ã«ã¹ã¯ãé掻æ§åãããïŒïŒ¢ ïŒïŒéºäŒåãïŒïŒ¢ ïŒïŒéºäŒåããŸãã¯ïŒ¥ïŒïŒ¢ ïŒïŒ/ïŒïŒ¢ ïŒïŒéºäŒåãæããããšãç¹åŸŽãšããè«æ±é ïŒã«èšèŒã®çµã¿æãã¢ãããŠã€ã«ã¹ã
- åèšçµã¿æãã¢ãããŠã€ã«ã¹ã¯ã掻æ§ã®ïŒ¥ïŒïŒ¡éºäŒåãå«ãããšãç¹åŸŽãšããè«æ±é ïŒã«èšèŒã®çµã¿æãã¢ãããŠã€ã«ã¹ã
- (a)çµã¿æãã¢ãããŠã€ã«ã¹ã®æ²»çåŠçæå¹éãåã³(b)è¬å€åŠçã«èš±å®¹ãããæ äœãå«ãè¬å€åŠçæè «ççµæç©ã§ãã£ãŠã
åèšçµã¿æãã¢ãããŠã€ã«ã¹ã¯ãã¢ãããŠã€ã«ã¹ã®ïŒ©ïŒŽïŒ²(inverted terminal repeat)ãã¯ã¬ãªããé ååã³ãªã©ã¯ã·ã³(relaxin)âãšã³ã³ãŒãã£ã³ã°ãã¯ã¬ãªããé åãå«ã¿ãåèšãªã©ã¯ã·ã³ã¯ãã¢ãããŠã€ã«ã¹ã®è «ççµç¹æµžéèœåã³è «ç现èã¢ãããŒã·ã¹ãèªå°ãããããã®æè «ççµæç©ã - åèšçµã¿æãã¢ãããŠã€ã«ã¹ã¯ãïŒéºäŒåé åãæ¬ å€±ããããã®ã§ãã£ãŠãåèšãªã©ã¯ã·ã³âãšã³ã³ãŒãã£ã³ã°ãã¯ã¬ãªããé åã¯ãåèšïŒ¥ïŒéºäŒåé åã®äœçœ®ã«æ¿å ¥ãããããšãç¹åŸŽãšããè«æ±é ïŒïŒã«èšèŒã®æè «ççµæç©ã
- åèšçµã¿æãã¢ãããŠã€ã«ã¹ã¯ãé掻æ§åãããïŒïŒ¢ ïŒïŒéºäŒåãïŒïŒ¢ ïŒïŒéºäŒåããŸãã¯ïŒ¥ïŒïŒ¢ ïŒïŒ/ïŒïŒ¢ ïŒïŒéºäŒåãæããããšãç¹åŸŽãšããè«æ±é ïŒïŒã«èšèŒã®æè «ççµæç©ã
- åèšçµã¿æãã¢ãããŠã€ã«ã¹ã¯ã掻æ§ã®ïŒ¥ïŒïŒ¡éºäŒåãå«ãããšãç¹åŸŽãšããè«æ±é ïŒïŒã«èšèŒã®æè «ççµæç©ã
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2004-0021601 | 2004-03-30 | ||
KR20040021601 | 2004-03-30 | ||
PCT/KR2005/000921 WO2006075819A1 (en) | 2004-03-30 | 2005-03-30 | Gene delivery system containing relaxin gene and pharmaceutical composition using relaxin |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2007531519A JP2007531519A (ja) | 2007-11-08 |
JP2007531519A5 true JP2007531519A5 (ja) | 2011-04-14 |
JP4764872B2 JP4764872B2 (ja) | 2011-09-07 |
Family
ID=36677826
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007506082A Active JP4764872B2 (ja) | 2004-03-30 | 2005-03-30 | ãªã©ã¯ã·ã³éºäŒåãå«ãéºäŒåäŒéã·ã¹ãã åã³ãªã©ã¯ã·ã³ãçšããè¬å€åŠççµæç© |
Country Status (6)
Country | Link |
---|---|
US (4) | US20070202080A1 (ja) |
EP (1) | EP1729817B1 (ja) |
JP (1) | JP4764872B2 (ja) |
KR (1) | KR100749857B1 (ja) |
CN (1) | CN1968717B (ja) |
WO (1) | WO2006075819A1 (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7878978B2 (en) | 2004-03-18 | 2011-02-01 | University Of Pittsburgh- Of The Commonwealth System Of Higher Education | Use of relaxin to increase arterial compliance |
US20070202080A1 (en) * | 2004-03-30 | 2007-08-30 | Industry-University Cooperation Foundation Yonsei | Gene Delivery System Containing Relaxin Gene And Pharmaceutical Composition Using Relaxin |
US20080107630A1 (en) * | 2006-04-10 | 2008-05-08 | New York University | Human matrix metalloproteinase-8 gene delivery enhances the oncolytic activity of a replicating adenovirus |
MX2010012502A (es) * | 2008-05-16 | 2011-04-11 | Corthera Inc | Metodo para el tratamiento de insuficiencia cardiaca cronica. |
GB2462221B (en) | 2008-05-16 | 2010-09-01 | Corthera Inc | Administration of relaxin to reduce diuretic use in humans with acute decompensated heart failure |
EP2971008B1 (en) | 2013-03-14 | 2018-07-25 | Salk Institute for Biological Studies | Oncolytic adenovirus compositions |
BR112016009572A2 (pt) * | 2013-11-07 | 2017-09-19 | Shanghai hengrui pharmaceutical co ltd | Análogo de relaxina humana, composição farmacêutica do mesmo e aplicação farmacêutica do mesmo |
JP7054527B2 (ja) | 2016-02-23 | 2022-04-14 | ãœãŒã¯ ã€ã³ã¹ãã£ãã¥ãŒã ãã©ãŒ ãã€ãªããžã«ã« ã¹ã¿ãã£ãŒãº | ã¢ãããŠã€ã«ã¹ã®è€è£œåæ ã枬å®ããããã®é«ã¹ã«ãŒãããã¢ãã»ã€ |
JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ãœãŒã¯ ã€ã³ã¹ãã£ãã¥ãŒã ãã©ãŒ ãã€ãªããžã«ã« ã¹ã¿ãã£ãŒãº | ãŠã€ã«ã¹åæ ãžã®åœ±é¿ãæå°éã«ããããã®æ²»ççšã¢ãããŠã€ã«ã¹ã«ãããå€å æ§éºäŒåçºçŸ |
SG11201810256XA (en) * | 2016-05-18 | 2018-12-28 | Modernatx Inc | Polynucleotides encoding relaxin |
KR102056066B1 (ko) * | 2016-12-09 | 2019-12-17 | ì§ë©ëì 죌ìíì¬ | ìží¬ìž êž°ì§ ë¶íŽ ìžì륌 ë°ííë ì¬ì¡°í© ìë°ë žë°ìŽë¬ì€ë¥Œ í¬íšíë íìì© ì¡°ì±ë¬Œ |
CA3045892A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
EP3591041A4 (en) * | 2017-02-28 | 2021-01-06 | Genemedicine Co., Ltd. | ANTI-CANCER COMPOSITION CONSISTING OF A TUMOR-SPECIFIC ONCOLYTIC ADENOVIRUS AND AN IMMUNE CHECKPOINT INHIBITOR |
CN109576231B (zh) * | 2017-09-28 | 2022-03-25 | å京康äžèŸŸå»è¯ç§ææéå ¬åž | å犻çéç»æº¶ç€è ºç æ¯ãè¯ç©ç»åç©åå ¶åšæ²»çè¿ç€å/æçççè¯ç©äžççšé |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6013638A (en) * | 1991-10-02 | 2000-01-11 | The United States Of America As Represented By The Department Of Health And Human Services | Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung |
US5998205A (en) * | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
US6719977B1 (en) * | 1998-02-12 | 2004-04-13 | The General Hospital Corporation | Methods to potentiate cancer therapies |
WO1999040929A1 (en) * | 1998-02-12 | 1999-08-19 | The General Hospital Corporation | Methods to potentiate cancer therapies |
DE60017924T2 (de) * | 1999-09-17 | 2006-03-30 | Tgt Laboratories, S.A. De C.V. | Rekombinante, adenovirale vektoren und ihre verwendung zur behandlung von leberzirrhose |
ATE362770T1 (de) * | 2000-02-09 | 2007-06-15 | Bas Medical Inc | Verwendung von relaxin zur behandlung von durch gefÀssverengung bedingten erkrankungen |
US6686196B2 (en) * | 2000-05-03 | 2004-02-03 | University Of Washington | Recombinant, modified adenoviral vectors for tumor specific gene expression and uses thereof |
US6946126B2 (en) * | 2001-06-04 | 2005-09-20 | Duke University | Replicating adenovirus vectors |
WO2002101012A2 (en) | 2001-06-08 | 2002-12-19 | Children's Hospital Research Foundation | Regulation of transgene expression following aav transduction |
KR100528727B1 (ko) * | 2002-04-30 | 2005-11-15 | ì€ì±ì¥ | ì¢ ì í¹ìŽì ìŽë©° ìží¬ ê³ ì¬ë¥Œ ì ë°íì¬ ê°ì ë ì¢ ì ìŽìíšê³Œë¥Œ ëíëŽë ì¬ì¡°í© ìë°ë žë°ìŽë¬ì€ ë° ìŽë¥Œ í¬íšíëìœì íì íì¢ ì ì¡°ì±ë¬Œ |
US20070202080A1 (en) * | 2004-03-30 | 2007-08-30 | Industry-University Cooperation Foundation Yonsei | Gene Delivery System Containing Relaxin Gene And Pharmaceutical Composition Using Relaxin |
WO2005115435A2 (en) * | 2004-04-30 | 2005-12-08 | Bas Medical, Inc. | Methods and compositions for control of fetal growth via modulation of relaxin |
-
2005
- 2005-03-30 US US10/599,521 patent/US20070202080A1/en not_active Abandoned
- 2005-03-30 CN CN2005800107101A patent/CN1968717B/zh active Active
- 2005-03-30 WO PCT/KR2005/000921 patent/WO2006075819A1/en not_active Application Discontinuation
- 2005-03-30 JP JP2007506082A patent/JP4764872B2/ja active Active
- 2005-03-30 EP EP05856302.4A patent/EP1729817B1/en active Active
- 2005-03-30 KR KR1020050026808A patent/KR100749857B1/ko active IP Right Grant
-
2015
- 2015-02-20 US US14/627,583 patent/US20150368669A1/en not_active Abandoned
-
2019
- 2019-05-02 US US16/401,614 patent/US20190323035A1/en not_active Abandoned
-
2022
- 2022-10-28 US US17/976,062 patent/US20230054820A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007531519A5 (ja) | ||
ES2310924T3 (es) | Vectores adenovirales defectivos y utilizacion en terapia genica. | |
US7067310B2 (en) | Method for the preparation of a viral vector by inter-molecular homologous recombination | |
ES2264123T3 (es) | Adenovirus recombinantes defectivos para la terapia genica de tumores. | |
JP5807236B2 (ja) | çµã¿æããããéºäŒåçºçŸèª¿ç¯é åãæããè «çç¹ç°ççºçŸã®æ¹åãããéºäŒåäŒéã·ã¹ãã | |
JP3416143B2 (ja) | çµæããŠã€ã«ã¹ãã¯ã¿ãŒè£œé çšãã«ããŒãŠã€ã«ã¹ | |
US6475480B1 (en) | Use of adenoviral E4 reading frames to improve expression of a gene of interest | |
JP4982680B2 (ja) | ãã³ãªã³éºäŒåãå«ãè¬å€åŠçæè «ççµæç© | |
AU2001271549B2 (en) | Replication deficient adenoviral tnf vector | |
Balicki et al. | Gene therapy of human disease | |
JP2005515784A (ja) | ïœïœã«é¢é£ãã现è掻æ§ã調ç¯ããããã®ã¢ãããŠã€ã«ã¹ãã¯ã¿ãŒ | |
AU2001271549A1 (en) | Replication deficient adenoviral TNF vector | |
JP4361954B2 (ja) | ã¢ãããŠã£ã«ã¹æ žé žãå«æããå»è¬çšçµæç© | |
KR20190070890A (ko) | ì¬ì¡°í© ìë°ë žë°ìŽë¬ì€ ë° ìŽë¥Œ í¬íšíë ì€êž°ìží¬ | |
CA2323235A1 (en) | Adenoviral vectors for treating disease | |
JP2006502726A (ja) | æ¹åãããå ç«çæ³ | |
WO2006125381A1 (fr) | Virus du gene de ciblage tumoral zd55-il-24, son procede de construction et son application | |
Curiel et al. | Adenoviral vectors for gene therapy of inherited and acquired disorders of the lung | |
Havlik et al. | Gene therapy for liver metastases | |
KR100969171B1 (ko) | ì¢ ì í¹ìŽì ë°íìŽ ê°ì ë ì ì ìì ë¬ì²Ž | |
WO2000022124A2 (en) | Methods and compositions to induce antitumor response | |
KR100993881B1 (ko) | ì ì ì ì ë¬ì²Žì ì ì ì ì ë¬íšìš ê°ì ë° ë°ìŽë¬ì€ 볎졎ì©ì¡°ì±ë¬Œ | |
KR101909905B1 (ko) | ì ì€êž°ìží¬ ë° ììží¬ í¹ìŽì ì ì ì ë°í ìì€í | |
Del Papa | Assessing the Oncolytic Capacity of Conditionally Replicating Adenovirus Armed with p14 Fusion Associated Small Transmembrane Protein and the Adenovirus Death Protein | |
US20030223962A1 (en) | Delivery of gene products to the lung parenchyma via gene transfer to the pleura |